Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

生物技术研究

Waltham,Massachusetts 10,597 位关注者

Framing the future of autoimmune diseases

关于我们

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

网站
https://www.viridiantherapeutics.com
所属行业
生物技术研究
规模
51-200 人
总部
Waltham,Massachusetts
类型
上市公司
创立
2007

地点

  • 主要

    203 Crescent St

    Building 17, Suite 102B

    US,Massachusetts,Waltham,02453

    获取路线
  • 6200 Lookout Road

    US,Colorado,Boulder,80301

    获取路线

Viridian Therapeutics, Inc.员工

动态

相似主页

查看职位

融资